Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Patient Education
Share your love
Q&A: Understanding Medicare payment shifts in eye care | Ophthalmology Times
Dustin D. French, PhD, examines 2 decades of Medicare reimbursement trends in ophthalmology, highlighting how changes in conversion factors, relative value units, and practice settings are affecting subspecialties and practice sustainability. (Image credit: AdobeStock/thatinchan) Medicare reimbursement for ophthalmology procedures has…
STAAR, Broadwood reach cooperation agreement, restructure board after terminated Alcon deal | Ophthalmology Times
(Image Credit: AdobeStock/Svyatoslav Lypynskyy) After the termination of the proposed acquisition by Alcon, STAAR has announced changes to its board of directors in a cooperation agreement with Broadwood Partners.1 Broadwood Partners and its affiliates are the largest private stockholders in…
PRIMA retinal implant restores vision in patients with advanced GA | Ophthalmology Times
(Image Credit: AdobeStock/stockbusters) An editorial published in the New England Journal of Medicine1 referred to the Photovoltaic Retina Implant Microarray (PRIMA) Implant (Science Corporation) as “the first treatment to restore vision” in patients with advanced geographic atrophy (GA) associated with…
Ocugen releases positive preliminary 12-month data from phase 2 ArMaDa trial | Ophthalmology Times
(Image Credit: AdobeStock/LORA) Ocugen has announced positive preliminary 12-month data from its phase 2 ArMaDa trial evaluating OCU410 (AAV5-RORA) for the treatment of geographic atrophy secondary to dry age-related macular degeneration. OCU410 is an investigational, intravitreally administered, AAV5-based gene therapy…
Ophthalmology pipeline watch: Key trial results and PDUFA dates for Q1 2026 | Ophthalmology Times
(Image Credit: AdobeStock/Iuliia Pilipeichenko) Editor’s Note: This content was generated with the assistance of AI. Clinical trial watchers can anticipate the release of data from a number of trials in the first quarter of 2026. The trials focus on Leber hereditary…
Rayner announces Sophi Phaco System in the US | Ophthalmology Times
The FDA has given 501(k) clearance to Rayner’s Sophi (Swiss Ophthalmology Innovation) Phacoemulsification System, making it available to cataract surgeons in the US, according to the company.1 The platform was designed with a focus on mobility, simplicity, and safety, which…
Ocugen publishes phase 1 GARDian1 gene therapy data for Stargardt disease | Ophthalmology Times
(Image Credit: AdobeStock/amazing studio) Ocugen has announced the publication of positive results from its phase 1 GARDian1 trial of OCU410ST, a gene therapy for Stargardt disease. Data was published in the peer-reviewed journal Nature Eye, which is published by the Royal…
FDA clears first daily disposable EDOF contact lens for presbyopia | Ophthalmology Times
The US FDA has officially cleared the first and only daily disposable soft (hydrophilic) contact lens for presbyopia that utilizes patented Extended Depth of Focus (EDOF) optical design technology.1 The Cataltheia Group and its US subsidiary Bruno Vision Care stated…
Exploring Emerging Therapies in the Retinal Vascular Disease Pipeline | Ophthalmology Times
The final segment highlights the rapidly evolving pipeline of retinal vascular disease therapies and offers closing reflections from the panelists. The discussion emphasizes the promise of next-generation agents, including sustained-release implants, tyrosine kinase inhibitors (TKIs), and gene therapies. TKIs are…
Study shows significant ocular changes following hemodialysis | Ophthalmology Times
(Image Credit: AdobeStock/Kiryl Lis) A new study from Poland found that one session of hemodialysis caused changes in the anterior and posterior segments of the eye.1 The investigators, led by Joanna Roskal-Wałek, MD, published their results in the Journal of…